Cargando…

Low-risk prostate cancer in India: Is active surveillance a valid treatment option?

INTRODUCTION AND OBJECTIVE: Carcinoma prostate is considered highly aggressive in Asian countries such as India. This raises an argument whether active surveillance (AS) gives a false sense of security as opposed to upfront radical prostatectomy (RP) in Indian males with low-risk prostate cancer (PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Shanky, Patil, Saurabh, Tamhankar, Ashwin Sunil, Ahluwalia, Puneet, Gautam, Gagan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531380/
https://www.ncbi.nlm.nih.gov/pubmed/33082633
http://dx.doi.org/10.4103/iju.IJU_37_20
_version_ 1783589754113097728
author Singh, Shanky
Patil, Saurabh
Tamhankar, Ashwin Sunil
Ahluwalia, Puneet
Gautam, Gagan
author_facet Singh, Shanky
Patil, Saurabh
Tamhankar, Ashwin Sunil
Ahluwalia, Puneet
Gautam, Gagan
author_sort Singh, Shanky
collection PubMed
description INTRODUCTION AND OBJECTIVE: Carcinoma prostate is considered highly aggressive in Asian countries such as India. This raises an argument whether active surveillance (AS) gives a false sense of security as opposed to upfront radical prostatectomy (RP) in Indian males with low-risk prostate cancer (PCa). We analyzed our prospectively maintained robot-assisted RP (RARP) database to address this question. MATERIALS AND METHODS: Five hundred and sixty-seven men underwent RARP by a single surgical team from September 2013 to September 2019. Of these, 46 (8.1%) were low risk considering the National Comprehensive Cancer Network criteria. Gleason grade group and stage were compared before and after surgery to ascertain the incidence of upgrading and upstaging. Preoperative clinical and pathological characteristics were analyzed for association with the probability of upstaging and upgrading. RESULTS: The mean age was 60.8 ± 6.8 years. Average prostate-specific antigen level was 6.7 ± 2.0 ng/mL. 40 (86.9%) patients had a T1 stage disease and 6 (13%) patients were clinically in T2a stage. A total of 25 (54.3%) cases were either upstaged or upgraded, 19 (41.3%) showed no change, and the remaining 2 (4.3%) had no malignancy on the final RP specimen. Upstaging occurred in 8 (17.4%) cases: 5 (10.9%) to pT3a and 3 (6.5%) to pT3b. Upgrading occurred in 23 (50%) cases: 19 (41.3%) to Grade 2; 3 (6.5%) to Grade 3; and 1 (2.2%) to Grade 4. CONCLUSIONS: There is a 50% likelihood of upstaging or upgrading in Indian males with low-risk PCa eligible for AS. Decision to proceed with AS should be taken carefully.
format Online
Article
Text
id pubmed-7531380
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-75313802020-10-19 Low-risk prostate cancer in India: Is active surveillance a valid treatment option? Singh, Shanky Patil, Saurabh Tamhankar, Ashwin Sunil Ahluwalia, Puneet Gautam, Gagan Indian J Urol Original Article INTRODUCTION AND OBJECTIVE: Carcinoma prostate is considered highly aggressive in Asian countries such as India. This raises an argument whether active surveillance (AS) gives a false sense of security as opposed to upfront radical prostatectomy (RP) in Indian males with low-risk prostate cancer (PCa). We analyzed our prospectively maintained robot-assisted RP (RARP) database to address this question. MATERIALS AND METHODS: Five hundred and sixty-seven men underwent RARP by a single surgical team from September 2013 to September 2019. Of these, 46 (8.1%) were low risk considering the National Comprehensive Cancer Network criteria. Gleason grade group and stage were compared before and after surgery to ascertain the incidence of upgrading and upstaging. Preoperative clinical and pathological characteristics were analyzed for association with the probability of upstaging and upgrading. RESULTS: The mean age was 60.8 ± 6.8 years. Average prostate-specific antigen level was 6.7 ± 2.0 ng/mL. 40 (86.9%) patients had a T1 stage disease and 6 (13%) patients were clinically in T2a stage. A total of 25 (54.3%) cases were either upstaged or upgraded, 19 (41.3%) showed no change, and the remaining 2 (4.3%) had no malignancy on the final RP specimen. Upstaging occurred in 8 (17.4%) cases: 5 (10.9%) to pT3a and 3 (6.5%) to pT3b. Upgrading occurred in 23 (50%) cases: 19 (41.3%) to Grade 2; 3 (6.5%) to Grade 3; and 1 (2.2%) to Grade 4. CONCLUSIONS: There is a 50% likelihood of upstaging or upgrading in Indian males with low-risk PCa eligible for AS. Decision to proceed with AS should be taken carefully. Wolters Kluwer - Medknow 2020 2020-07-01 /pmc/articles/PMC7531380/ /pubmed/33082633 http://dx.doi.org/10.4103/iju.IJU_37_20 Text en Copyright: © 2020 Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Singh, Shanky
Patil, Saurabh
Tamhankar, Ashwin Sunil
Ahluwalia, Puneet
Gautam, Gagan
Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title_full Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title_fullStr Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title_full_unstemmed Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title_short Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
title_sort low-risk prostate cancer in india: is active surveillance a valid treatment option?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531380/
https://www.ncbi.nlm.nih.gov/pubmed/33082633
http://dx.doi.org/10.4103/iju.IJU_37_20
work_keys_str_mv AT singhshanky lowriskprostatecancerinindiaisactivesurveillanceavalidtreatmentoption
AT patilsaurabh lowriskprostatecancerinindiaisactivesurveillanceavalidtreatmentoption
AT tamhankarashwinsunil lowriskprostatecancerinindiaisactivesurveillanceavalidtreatmentoption
AT ahluwaliapuneet lowriskprostatecancerinindiaisactivesurveillanceavalidtreatmentoption
AT gautamgagan lowriskprostatecancerinindiaisactivesurveillanceavalidtreatmentoption